Anti-cancer effects of F16: A novel vascular endothelial growth factor receptor-specific inhibitor.

Rathinavelu A, Alhazzani K, Dhandayuthapani S, Kanagasabai T. Anti-cancer effects of F16: A novel vascular endothelial growth factor receptor-specific inhibitor. Tumour Biol. 2017 Nov; 39(11):1010428317726841.

View in: PubMed

subject areas

Angiogenesis Inhibitors
Animals
Antineoplastic Agents
Breast Neoplasms
Cell Movement
Cell Proliferation
Female
Humans
Indoles
Mice
Mice, Nude
Neovascularization, Pathologic
Pyridinium Compounds
Vascular Endothelial Growth Factor Receptor-2
Xenograft Model Antitumor Assays

authors with profiles

Thanigaivelan

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support